This year represents a major milestone in our journey to make eye care simpler, more connected and more intelligent for everyone, everywhere. Join us at any of our international stops to see our latest innovations in action.
Explore our full 2026 calendar below to find dates and locations – we look forward to seeing you at the Phelcom booth!
Ophthalmology and Health CONFERENCES Phelcom will attend worldwide in 2026
We look forward to another amazing year of strengthening connections, sharing clinical insights, and showcasing how our technology transforms vision care and improves patient outcomes across the globe. We’ll see you on the road in 2026!
For Phelcom, 2025 was a pivotal year defined by global scientific validation and critical mission expansion. With the publication of a key scientific article about the Eyer portable fundus camera datasets and the expansion of our operations into several new countries, we reinforced our commitment to increasing access to vital eye care and contributing to the prevention of visual impairment and blindness globally.
Explore the key milestones leading up to Phelcom’s 10th anniversary!
Scientific Recognition: Publication in Nature Portfolio
Capture being performed with Eyer during the Itabuna Diabetes Screening Campaign in 2022
2025 marked a major milestone for the Eyer technology, as its datasets were featured in one of the world’s most respected scientific journals.
Scientific Data, a journal from the Nature portfolio, published the article“A portable retina fundus photos dataset for clinical, demographic and diabetic retinopathy prediction,” introducingmBRSET: the first-ever publicly available dataset of diabetic retinopathy images captured using a handheld fundus camera in a real-world, high-burden setting. The images were collected during the 2022 Itabuna Diabetes Screening Campaign (Mutrião do Diabetes) in Bahia, Brazil, demonstrating the real-world utility and quality of the Eyer device.
Driving Impact: Screening Campaigns Across Brazil
Capture being performed with Eyer2 during the Itabuna Diabetes Screening Campaign in 2025
Phelcom’s commitment to preventative eye care was demonstrated through our participation in major screening campaigns across Brazil, including initiatives in Itabuna (BA), Blumenau (SC), and São Paulo (SP). Our equipment played a pivotal role in ensuring efficient and effective care delivery.
The Diabetes Screening Campaign in Blumenau, registered over 1,300 scheduled visits. Using the Eyer, approximately 190 cases of diabetic retinopathy were identified at varying severity levels, with patients subsequently referred for treatment and further testing. Eyer’s Artificial Intelligence technology also allowed for the immediate discharge of approximately 290 patients (screening negatively for pathology), significantly optimizing clinical patient throughput.
In Itabuna, where more than 2,000 consultations were performed, we showcased innovation beyond the lens. The campaign utilized “Mutirômetro,” a dedicated app developed by Phelcom to completely digitize the patient journey and streamline the care processes from start to finish.
Phelcom’s technology also supported the 28th National Free Diabetes Campaign, a massive effort promoted by the National Association for Diabetes Care (ANAD) in partnership with FENAD. This event, held on November 1st, provided critical educational, physical activity promotion, and specialized care, further proving the Eyer’s utility in large-scale health initiatives.
Global Growth: Expansion into Latin America
Phelcom booth at Faco Extrema 2025, held in Buenos Aires, Argentina, from August 21 to 23.
2025 was the year Phelcom solidified its commitment to making high-quality eye care accessible across Latin America. Through powerful strategic partnerships, we successfully expanded the commercial availability of the Eyer portable fundus camera. Our technology is now officially accessible to eye care providers and patients in the key markets of Chile, Argentina, and Colombia.
The strong and positive receptivity from the Latin American market underscored the adaptability and essential reach of the solutions Phelcom develops. This expansion proves that innovative, portable technology like the Eyer is uniquely positioned to address high-burden health challenges across diverse global regions.
Investing in the Next Generation: The “Eyes to the Future” Contest
Participating leagues of the 2nd edition of the “Eyes to the Future” (De Olhos para o Futuro) contest during the award ceremony at SIMASP 2025.
Phelcom is dedicated not just to building great technology, but also to training the next generation of medical leaders. The second edition of our “Eyes to the Future” (De Olhos para o Futuro) contest, held in partnership with the Brazilian Association of Academic Ophthalmology Leagues (ABLAO), achieved significant social impact while also educating future doctors. The contest mobilized 205 medical students across seven different states, resulting in 2,486 vital eye screenings. More than 70 patients with severe conditions were diagnosed and referred for treatment with the support of the Eyer portable fundus camera and EyerMaps AI.
The winning projects powerfully demonstrated how portable technologies are key to expanding access to accurate diagnosis across diverse geographic and socioeconomic contexts in Brazil, proving that the future of eye care is both mobile and intelligent.
Strengthening Presence: Global Visibility and Market Reach
Phelcom booth at Academy 2025, held in Boston, United States, from October 8 to 11.
Phelcom’s achievements in 2025 were underscored by our intense market presence and global visibility. We intensified our participation in key ophthalmology events, featuring over 60 commercial exhibitions and institutional sponsorships at major conferences across Brazil, The United States, and Latin America. This visibility demonstrates our commitment to collaborating with and supporting the global eye care community.
Counting Down to a Decade of Innovation
The remarkable results achieved in 2025 serve as the perfect prelude to a significant milestone: in 2026, Phelcom will celebrate its 10th anniversary.
This coming year will be marked by numerous developments, innovations and celebrations. What began a decade ago as a project by three dedicated researchers has successfully transformed into a global benchmark for portability and intelligence applied to ophthalmology, with a strong, continued outlook for expansion and life-changing innovation.
About Phelcom
Phelcom Technologies is an American-Brazilian medtech company pioneering solutions in digital visual health. We leverage our deep expertise in Physics, Electronics, and Computing (Phelcom) to create technology that makes eye care simpler, smarter and more connected.
Phelcom was founded in 2016 by three dedicated researchers: Computer Engineer José Augusto Stuchi, Electronic Engineer Flavio Pascoal Vieria, and Physicist Diego Lencione. Inspired by the vision struggles of co-founder Diego Lencione’s brother, the founders set out to democratize eye diagnostics by developing a portable retinal camera with an integrated smartphone.
In 2019, Phelcom launched its first product, the Eyer, a portable retinal camera designed for mobility and ease of use. In 2024, the company introduced the Eyer2 a comprehensive photo documentation platform capable of capturing high-quality images of both the posterior and anterior segments of the eye.
To date, Phelcom’s innovative technology has benefitted over two million people across multiple countries, including the United States, Japan, Chile, Colombia, the United Arab Emirates, and Brazil. Our devices have also played a crucial role in over 100 social outreach initiatives, reinforcing our core mission to prevent visual impairment and blindness.
Since its inception, Phelcom Technologies has consistently valued building strong partnerships with institutions that share the same purpose: promoting access to visual health through technology. Throughout its history, the company has received support from key innovation and research centers that were fundamental to the development of its first products.
SUPERA Innovation and Technology Park in Ribeirão Preto (SP) and Eretz.bio — the startup incubator of Hospital Israelita Albert Einstein — played an essential role during Phelcom’s incubation period and the creation of its first prototypes.
During the testing and clinical validation stages of Eyer, Phelcom’s first portable fundus camera, the company collaborated with leading institutions such as the Federal University of São Paulo (Unifesp), the Hospital do Amor de Barretos (SP), the Vision Institute (IPEPO), and the Ribeirão Preto Medical School Clinical Hospital (HCFMRP-USP).
International partnerships have also contributed to Phelcom’s technological advancements, such as the collaboration with Allm Inc., a Japanese company specializing in medical technologies, and with Hospital Israelita Albert Einstein itself, which continues to be a strategic partner in innovation projects.
New Investment
In October 2025, Phelcom received a new investment from J&J Impact Ventures, an investment fund within the J&J Foundation, which supports a global portfolio of early-stage companies transforming access to quality and affordable healthcare. With this funding, Phelcom will accelerate its innovation journey and ongoing commitment to democratize access to eye exams through development to enhance its current portfolio as well as creating new technologies.
About Phelcom
Phelcom Technologies is an American-Brazilian company that employs Physics, Electronics, and Computing to make visual health simpler, more connected, and smart.
Founded in 2016 by three young researchers: José Augusto Stuchi- a computer engineer, Flavio Pascoal Vieira- an electronic engineer, and Diego Lencione- a physicist. Inspired by co-founder Diego’s brother, who had struggled with a severe vision condition since childhood, the three founders set out to develop a portable retinal camera with an integrated smartphone.
In 2019, Phelcom launched its first product, the Eyer, A portable retinal camera. Five years later, the company introduced the Eyer2, a photo documentation platform capable of capturing high-quality images of both the posterior and anterior segments.
To date, Phelcom’s technology has benefited over two million people across multiple countries, including the United States, Japan, Chile, Colombia, the United Arab Emirates and Brazil. It has also been used in over 100 social outreach initiatives.
Phelcom Technologies is proud to expand its mission of transforming eye care globally. The company’s presence in the United States is a key part of that journey, led by a passionate team based in Cambridge, Massachusetts.
Located in the heart of Kendall Square, Phelcom is housed at the Cambridge Innovation Center (CIC), a vibrant innovation hub that fosters collaboration, growth, and innovation.
“Being located in such a vibrant healthcare ecosystem like Cambridge is important because it helps us build relationships with world-class doctors and the best innovators in the world,” says Gabriel Finch, Sales and Business Development Supervisor for the US Market.
It’s a natural fit for Phelcom, whose mission is to make visual health more accessible through innovative tools like the Eyer2 — a portable, versatile fundus camera transforming the way photo documentation is performed.
Cambridge Innovation Center (CIC), Cambridge, Massachusetts.
US Team
The US team is composed of four professionals focused on sales, business development, marketing and customer success.
Beyond the technology, the company culture is a key driver. “I love the team spirit, even across countries I always feel supported and connected,” shares Marcela Martins, whose main focus is prospecting.
For Finch, what stands out is the global aspect of Phelcom’s work. “Getting to work with clients all over the world, whether it be from South America to Japan, to the Middle East, to Europe, it’s a wide breadth of types of doctors that we get to talk to and all from different parts of the globe”.
In addition to supporting the growing US customer base, the team collaborates closely with colleagues in Brazil, reflecting Phelcom’s strong international spirit.
“My favorite thing about Phelcom is being able to work with our international team in Brazil as well as our team in the Cambridge office,” says Emily Homiller, the fourth sales professional that composes the US Team.
Phelcom US team members, from left to right: Marcela Martins, Gabriel Finch, Emily Jakacki and Emily Homiller.
Eyer2: An improved way to deliver eye care
At the heart of Phelcom’s innovation is the Eyer2 — a device designed to simplify workflows and expand access to high-quality eye care by combining portability, ease of use, and advanced imaging capabilities for both the posterior and anterior segments.
“With the Eyer2 camera, you bring the device to the patient, making workflow more efficient and patient-friendly. What many OD and MD practices love about it is that anyone in the clinic can easily capture high-quality images — and there’s no need to move patients from room to room,” explains Finch
The device’s panoramic imaging function is another key highlight. “It enables you to create a panoramic image with up to 120 degrees field of view — giving you wider retinal coverage with excellent detail,” adds Hulsander.
For Martins, two things stand out: “The image quality and how easy it is to use.” This accessibility is crucial for clinics of all sizes.
Portability is another key advantage, as Homiller points out: “My favorite thing about Eyer2 is its portability so it can reach underserved communities”.
By combining advanced technology with real-world usability, the Eyer2 is helping improve eye care on a global scale — making it easier for clinics to capture faster, more accurate, and more efficient eye images.
About Phelcom
Phelcom Technologies is an American-Brazilian company that employs Physics, Electronics, and Computing to make visual health simpler, more connected, and smart.
Founded in 2016 by three young researchers, the company developed a portable retinal camera with an integrated smartphone. Its first prototype was inspired by co-founder Diego Lencione’s personal experience, as his brother had struggled with a severe vision condition since childhood.
In 2019, Phelcom launched its first product, the Eyer portable retinal camera. Five years later, the company introduced the Eyer2, a photo documentation platform capable of capturing high-quality images of both the posterior and anterior segments.
To date, Phelcom’s technology has benefited over two million people across multiple countries, including the United States, Japan, Chile, Colombia, the United Arab Emirates and Brazil. It has also been used in over 100 social outreach initiatives.
Fundus imaging plays a crucial role in diagnosing and monitoring various eye diseases, including diabetic retinopathy. However, in many low- and middle-income countries, access to conventional retinal imaging equipment remains limited due to high costs and infrastructure requirements. Additionally, publicly available image datasets for doctors, researchers, and clinicians remain scarce, particularly for images captured with portable fundus cameras.
In this context, portable fundus cameras like the Eyer have emerged as a more accessible and cost-effective solution for eye screening and disease management. Mounted onto a smartphone, the Eyer captures high-quality retinal images in minutes—without requiring pupil dilation.
These devices can be used in a variety of settings beyond hospitals, such as community health screenings and remote telemedicine consultations. Additionally, they record detailed metadata typically unavailable in other datasets, including patient age, sex, diabetes duration, treatments, and comorbidities.
Recently, Scientific Data, a journal from the Nature portfolio, published the article “A portable retina fundus photos dataset for clinical, demographic, and diabetic retinopathy prediction,” introducing mBRSET: the first publicly available diabetic retinopathy dataset captured using handheld fundus cameras in real-world, high-burden environments. Among the authors of the study are ophthalmologist Fernando Korn Malerbi and Phelcom’s CEO, José Augusto Stuchi.
Fundus images captured with Eyer during the Itabuna Diabetes Campaign, held in 2022, highlighting the attention map generated by EyerMaps, indicating possible anomalies.
mBRSET: A Groundbreaking Dataset
mBRSET consists of 5,164 from 1,291 patients of diverse backgrounds, all captured with the Eyer device during the 2022 Itabuna Diabetes Campaign in Bahia. Recognized as one of the world’s largest diabetes prevention and treatment initiatives, this campaign provides hundreds of patients with vital screenings—such as fundus examinations—and referrals for specialized treatment.
Exam performed with Eyer during the Itabuna Diabetes Campaign, held in 2022.
To validate the utility of mBRSET, state-of-the-art deep learning models were trained for benchmarking, demonstrating high accuracy in diagnosing diabetic retinopathy and macular edema, as well as predicting demographic data.
An analysis of 4,885 assessed images revealed that 3,759 images (76.79%) showed no signs of diabetic retinopathy (DR), 272 images (5.56%) indicated mild non-proliferative DR, 570 images (11.64%) exhibited moderate non-proliferative DR, 82 images (1.67%) showed severe non-proliferative DR, 427 images (8.69%) displayed signs of macular edema.
A Milestone for Ocular Health and Scientific Research
The significance of the mBRSET dataset can be outlined in 5 key aspects:
Representing Brazil’s Diverse Population
mBRSET helps reduce the underrepresentation of low- and middle-income country (LMIC) populations in ophthalmological datasets by including individuals from various ethnic and socioeconomic backgrounds in Brazil.
The First Public Dataset with Portable Camera Images
This is the first publicly available dataset featuring images captured with portable fundus cameras, reflecting the increasing adoption of this technology in resource-limited settings.
Data Collection in Real-World, High-Demand Environments
Images were captured in high-volume clinical settings, ensuring the dataset accurately represents real-world challenges in eye disease screening and management.
Inclusion of Detailed Demographic Data
mBRSET goes beyond retinal images, incorporating information such as gender, education level, and health insurance status. This enables researchers to evaluate AI algorithm performance across different subpopulations.
A Foundation for AI Development in Ophthalmology
This dataset serves as a critical resource for training and validating AI algorithms, fostering advancements in automated screening, diagnosis, and monitoring of diabetic retinopathy and other eye conditions.
Phelcom CEO José Augusto Stuchi emphasizes the dataset’s impact on the scientific and medical communities:
“The creation of this mBRSET marks a significant milestone in ocular health, particularly for regions with limited resources. By providing high-quality images captured with portable devices, we expand research opportunities and accelerate the development of AI-driven solutions that can revolutionize the diagnosis and treatment of eye diseases.”
Diego Lencione, co-founder and CTO of Phelcom, Flavio Pascoal Vieira, co-founder and COO of Phelcom, Paulo Prado, coordinator of Mobile Software and AI at Phelcom, and José Augusto Stuchi, co-founder and CEO of Phelcom, during the Itabuna Diabetes Campaign, held in 2022.
Eyer
The Eyer is a portable fundus camera that attaches to a smartphone, enabling high-quality retina exams in just minutes—without the need for pupil dilation.
The technology supports the diagnosis of more than 50 diseases, including: glaucoma, cataracts, diabectic retinopathy, retinoblastoma, hypertensive retinopathy, retinopathy of prematurity, ocular toxoplasmosis.
Recently, Phelcom launched Eyer2, an enhanced version of the device featuring new built-in tools for expanded diagnostic capabilities. In addition to posterior eye imaging, Eyer2 enables the detection of anterior segment conditions such as: blepharitis and other eyelash abnormalities, meibomian gland dysfunction, styes, conjunctival and eyelid tumors, advanced cataracts, foreign bodies and burns, corneal injuries, keratitis caused by dry eye, contact lenses, infections and ulcers.
About Phelcom
Phelcom Technologies is a Brazilian medtech company based in São Carlos, São Paulo. Founded in 2016 by three young researches—a physicist, an electronics engineer, and a computer engineer—the company developed a portable retinal camera integrated with a smart phone.
The first prototype was inspired by co-founder Diego Lencione’s personal experience, as his brother struggled with a severe vision condition from childhood.
In 2019, Phelcom launched its first product, the Eyer portable retinal camera, in Brazil. Five years later, the company introduced the Eyer2, a platform capable of capturing high-quality images of both the posterior and anterior segments.
To date, Phelcom’s technology has benefited over two million people across Brazil and multiple countries, including the United States, Japan, Chile, Colombia and the United Arab Emirates. It has also been used in over 100 social outreach initiatives.
In November, Phelcom launched an upgraded version of Eyercloud, the online platform for managing ophthalmic examinations conducted using Eyer and Eyer2 portable fundus cameras. With significant advancements in data security, accessibility and design, the new version enhances the user experience, streamlines processes, and accelerates diagnoses, effectively meeting the needs of doctors and healthcare professionals.
Key updates in the new Eyercloud include the ability to view exams in grid or list format, simplified editing fields, and a refreshed design with more visible buttons and intuitive navigation. Additionally, users can now register patients and associate exams directly through the platform.
“We applied the new design language already present in Eyer2, unifying the Eyercloud interface with that of the device. Our aim is to offer an equally efficient and agile user experience on both platforms”, explains Phelcom’s marketing consultant and product designer, Edgard Regolão Junior.
Junior also emphasizes one of the key enhancements: the immediate display of retinal images on the homepage. “When the user accesses the platform, they can see the latest images and exams taken. This facilitates the quick analysis of the verification and classification already done by EyerMaps. This artificial intelligence detects possible abnormalities in seconds and displays a heatmap on the images. This feature speeds up the identification of alterations and allows professionals to make faster and more accurate diagnoses,” he adds.
Accessibility and security
Enhanced navigation is one of the most significant changes in EyerCloud. The platform is now simpler and faster to access, requiring fewer clicks and eliminating unnecessary steps. Additionally, data entry has been streamlined, allowing users to add, edit, and save information more intuitively and efficiently, making the tool more user-friendly for everyday use.
“The system has also been updated to enhance security, ensuring compliance with information and data protection regulations.,” says Phelcom’s Data Engineering Manager, Fernando Mineo Raze Yamanaka.
All the information stored on EyerCloud is protected by Amazon Web Services (AWS), a world reference in cloud solutions. The platform also strictly follows HIPAA guidelines (Health Insurance Portability and Accountability Act), guaranteeing maximum data protection and reliability.
Continuous improvement and customer support
EyerCloud facilitates communication with patients by displaying and sharing exams in a clear and accessible way.
Customers who have questions or suggestions can count on Phelcom’s support for quick and efficient assistance.
Yamanaka explains that the company keeps an organized list of user feedback and requests, prioritizing the most requested improvements to optimize the platform’s ongoing development. “We will continue to invest in improvements following this feedback. EyerCloud will become increasingly dynamic, with new features, filters and search methods to make it even easier for professionals to work with it”.
EyerCloud: safe and efficient management of ophthalmic exams
EyerCloud is an online platform designed to streamline the management of ophthalmic exams, delivering enhanced security, efficiency and convenience. Featuring an intuitive and user-friendly interface, the system enables seamless storage and sharing of exams and reports conducted with the Eyer and Eyer2 portable fundus cameras. Automatic synchronization ensures data is securely uploaded to the cloud, offering both reliability and accessibility.
This integration streamlines the workflow for healthcare professionals by ensuring exams are always accessible, well-organized, and securely protected. It also facilitates swift communication and efficient monitoring of results.
Discover the advantages of EyerCloud:
Connectivity
The platform is easily accessible via an Eyer or Eyer2 device, smartphone, tablet or computer. Even without an internet connection, exams are automatically saved and seamlessly uploaded to the cloud once internet connection is restored. Additionally, EyerCloud is fully compatible with leading electronic medical record systems, enabling smooth integration into the workflow of clinics and hospitals.
Artificial Inteligence
When integrated with EyerMaps, EyerCloud displays exams using a color-coded system to identify potential alterations, simplifying the prioritization of urgent cases:
Green: low probability of alteration (up to 30%).
Yellow: medium probability of alteration (31% to 70%).
Red: high probability of alteration (71% to 100%).
Transparency
Facilitate communication with patients by displaying and sharing exams in a clear and accessible way. EyerCloud enhances understanding of diagnoses and treatment progress, fostering greater patient trust and engagement.
Mobility
With EyerCloud, healthcare professionals can carry out examinations in the field while ophthalmologists report remotely, from anywhere in the world. This flexibility extends the reach of ophthalmic services and speeds up care.
One of the main improvements in the new EyerCloud is the immediate display of retinal images on the home page.
Security
The data stored in EyerCloud is protected by Amazon Web Services (AWS) infrastructure, guaranteeing maximum security and compliance with HIPAA (Health Insurance Portability and Accountability Act). In addition, the platform allows you to manage different levels of access, ensuring that each professional only sees the information they need.
About Phelcom
Phelcom Technologies is a Brazilian medtech company based in São Carlos, the interior of São Paulo. The company’s story began in 2016, when three young researchers – a physicist, an electronics engineer and a computer engineer (Physics, Electronics, Computing) – created a fundus camera integrated with a smartphone.
Phelcom’s first prototype was inspired by the personal experience of one of the partners, Diego Lencione, whose brother faced a serious condition that severely compromised his vision since childhood.
In 2019, Phelcom launched its first product to the Brazilian market: the Eyer portable fundus camera. Five years later, it launched the Eyer2, a platform that makes it possible to document the posterior and anterior segments with high quality images.
Today, Phelcom’s technology has benefited more than two million people worldwide, and has also been used in more than 100 social projects.
Português 
Español 
English 
